These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 2173004)
1. Pharmacological studies on the low molecular weight heparin derivative CY 216. Kaiser B; Kühnemuth G; Markwardt F Pharmazie; 1990 Jul; 45(7):522-4. PubMed ID: 2173004 [TBL] [Abstract][Full Text] [Related]
2. Experimental studies on the antithrombotic and haemorrhagic effects of heparin and a low molecular weight heparin derivative. Kaiser B; Hauptmann J; Markwardt F Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):119-25. PubMed ID: 2459005 [TBL] [Abstract][Full Text] [Related]
3. Recombinant full-length tissue factor pathway inhibitor (TFPI) prevents thrombus formation and rethrombosis after lysis in a rabbit model of jugular vein thrombosis. Kaiser B; Fareed J Thromb Haemost; 1996 Oct; 76(4):615-20. PubMed ID: 8903005 [TBL] [Abstract][Full Text] [Related]
4. Anticoagulant and antithrombotic action of the synthetic thrombin inhibitor D-phenylalanyl-L-prolyl-L-arginine nitrile. Kaiser B; Richter M; Hauptmann J; Markwardt F Pharmazie; 1991 Feb; 46(2):128-31. PubMed ID: 1852761 [TBL] [Abstract][Full Text] [Related]
5. Antithrombotic and haemorrhagic effects of the naturally occurring thrombin inhibitor hirudin. Kaiser B; Markwardt F Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):41-6. PubMed ID: 2459030 [TBL] [Abstract][Full Text] [Related]
6. Pharmacological properties of a low molecular weight butyryl heparin derivative (C4-CY 216) with long lasting effects. Saivin S; Petitou M; Lormeau JC; Dupouy D; Sié P; Caranobe C; Houin G; Boneu B Thromb Haemost; 1992 Mar; 67(3):346-51. PubMed ID: 1322569 [TBL] [Abstract][Full Text] [Related]
7. Interaction between the sulfated lactobionic acid (LW 10082) and other antithrombotic agents in animal thrombosis model. Giedrojć J; Krupiński K; Breddin HK; Bielawiec M Pol J Pharmacol; 1996; 48(3):317-22. PubMed ID: 9112669 [TBL] [Abstract][Full Text] [Related]
9. A comparative study of the anticoagulant and anti-thrombotic effects of unfractionated heparin and a low molecular weight heparin (Fraxiparine) in an experimental model of human venous thrombosis. Diquélou A; Dupouy D; Cariou R; Sakariassen KS; Boneu B; Cadroy Y Thromb Haemost; 1995 Nov; 74(5):1286-92. PubMed ID: 8607111 [TBL] [Abstract][Full Text] [Related]
10. A comparison of the antithrombotic and haemorrhagic effects of a low molecular weight heparin (LHN-1) and conventional heparin. Diness V; Nielsen JI; Pedersen PC; Wolffbrandt KH; Ostergaard PB Thromb Haemost; 1986 Jun; 55(3):410-4. PubMed ID: 3750271 [TBL] [Abstract][Full Text] [Related]
11. Antithrombotic effect of two low molecular weight thrombin inhibitors and a low-molecular weight heparin in a caval vein thrombosis model in the rat. Eriksson BI; Carlsson S; Halvarsson M; Risberg B; Mattsson C Thromb Haemost; 1997 Nov; 78(5):1404-7. PubMed ID: 9408027 [TBL] [Abstract][Full Text] [Related]
12. Antithrombotic and thrombolytic activity of heparins in a rat model of laser-induced thrombosis. Krupiński K; Giedrojć J; Breddin HK; Bielawiec M Pol J Pharmacol; 1996; 48(3):345-50. PubMed ID: 9112675 [TBL] [Abstract][Full Text] [Related]
13. Antithrombotic effects of heparin and related agents. Hladovec J; Kornalík F Cor Vasa; 1991; 33(1):68-74. PubMed ID: 1655354 [TBL] [Abstract][Full Text] [Related]
14. Comparative study on the antithrombotic effects of a synthetic thrombin inhibitor and of heparin in animal models. Hauptmann J; Barth A; Schönberger FP; Markwardt F Biomed Biochim Acta; 1983; 42(7-8):959-65. PubMed ID: 6651812 [TBL] [Abstract][Full Text] [Related]
15. Antithrombotic efficacy of a recombinant nematode anticoagulant peptide (rNAP5) in canine models of thrombosis after single subcutaneous administration. Rebello SS; Blank HS; Rote WE; Vlasuk GP; Lucchesi BR J Pharmacol Exp Ther; 1997 Oct; 283(1):91-9. PubMed ID: 9336312 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of platelet-dependent thrombosis by low molecular weight heparin (CY222): comparison with standard heparin. Cadroy Y; Harker LA; Hanson SR J Lab Clin Med; 1989 Oct; 114(4):349-57. PubMed ID: 2551985 [TBL] [Abstract][Full Text] [Related]
17. Comparison of thrombin active site and exosite inhibitors and heparin in experimental models of arterial and venous thrombosis and bleeding. Schumacher WA; Steinbacher TE; Heran CL; Seiler SM; Michel IM; Ogletree ML J Pharmacol Exp Ther; 1993 Dec; 267(3):1237-42. PubMed ID: 8263785 [TBL] [Abstract][Full Text] [Related]
18. Antithrombotic efficacy in a rat model of the low molecular weight heparin, reviparin sodium, administered by the oral route. Hiebert LM; Wice SM; Ping T; Herr D; Laux V Thromb Haemost; 2001 Jan; 85(1):114-8. PubMed ID: 11204561 [TBL] [Abstract][Full Text] [Related]
19. Arterial antithrombotic effects of aspirin, heparin, enoxaparin and clopidogrel alone, or in combination, in the rat. Daykin HJ; Sturgeon SA; Jones C; Wright CE Thromb Res; 2006; 118(6):755-62. PubMed ID: 16410020 [TBL] [Abstract][Full Text] [Related]
20. Antithrombotic activity of dermatan sulphates, heparins and their combination in an animal model of arterial thrombosis. Iacoviello L; D'Adamo MC; Pawlak K; Polishchuck R; Wollny T; Buczko W; Donati MB Thromb Haemost; 1996 Dec; 76(6):1102-7. PubMed ID: 8972038 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]